Naruse N, Tenmyo O, Kawano K, Tomita K, Ohgusa N, Miyaki T, Konishi M, Oki T
Bristol-Myers Squibb Research Institute, Tokyo, Japan.
J Antibiot (Tokyo). 1991 Jul;44(7):733-40. doi: 10.7164/antibiotics.44.733.
Five unidentified actinomycete strains produced a series of novel antiviral antibiotics which have a unique 2,6-dialkyl-10-ethyl-3(or 9)-hydroxy-13-tridecanelactam nucleus substituted with 3-amino-3,6-dideoxy-L-talose or 3-amino-3,6-dideoxy-L-mannose(L-mycosamine). The antibiotic components exhibited potent inhibitory activity against influenza virus type A Victoria strain infection in Madin Darby canine kidney cells by the cytopathic effect reduction assay.